$4 Billion is the total value of BVF INC/IL's 70 reported holdings in Q4 2023. The portfolio turnover from Q3 2023 to Q4 2023 was 70.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RVMD | Buy | REVOLUTION MEDICINES INC | $171,541,160 | +55.7% | 5,981,212 | +50.2% | 4.29% | +44.4% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $131,419,453 | +99.5% | 5,161,801 | +8.9% | 3.29% | +85.2% |
| KURA | Buy | KURA ONCOLOGY INC | $106,027,019 | +72.7% | 7,373,228 | +9.5% | 2.65% | +60.3% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $75,435,280 | -24.7% | 10,333,600 | +24.6% | 1.89% | -30.1% |
| ACIU | Buy | AC IMMUNE SA | $72,856,180 | +244.1% | 14,571,236 | +96.2% | 1.82% | +219.3% |
| GHRS | Buy | GH RESEARCH PLCordinary shares | $60,320,916 | -35.3% | 10,400,158 | +12.1% | 1.51% | -39.9% |
| ETNB | Buy | 89BIO INC | $45,208,944 | +58.6% | 4,047,354 | +119.2% | 1.13% | +47.1% |
| RLAY | Buy | RELAY THERAPEUTICS INC | $43,710,195 | +119.7% | 3,970,045 | +67.8% | 1.09% | +103.7% |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $40,518,750 | – | 1,875,000 | +100.0% | 1.01% | – |
| LXRX | Buy | LEXICON PHARMACEUTICALS INC | $37,386,517 | +71.5% | 24,435,632 | +22.2% | 0.94% | +59.2% |
| ANNX | New | ANNEXON INC | $31,780,000 | – | 7,000,000 | +100.0% | 0.80% | – |
| New | ENGENE HOLDINGS INC | $20,777,072 | – | 2,251,037 | +100.0% | 0.52% | – | |
| New | SPYRE THERAPEUTICS INC | $14,785,962 | – | 687,080 | +100.0% | 0.37% | – | |
| New | VISTAGEN THERAPEUTICS INC | $10,280,000 | – | 2,000,000 | +100.0% | 0.26% | – | |
| IKNA | Buy | IKENA ONCOLOGY INC | $9,395,253 | -31.5% | 4,769,164 | +50.5% | 0.24% | -36.5% |
| New | SAB BIOTHERAPEUTICS INC | $6,310,069 | – | 9,178,282 | +100.0% | 0.16% | – | |
| New | ENGENE HOLDINGS INC*w exp 10/31/202 | $803,592 | – | 945,402 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 37 | Q4 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 32 | Q1 2024 | 2.8% |
| XOMA CORP DEL | 31 | Q2 2024 | 7.3% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| CYTOMX THERAPEUTICS INC | 29 | Q2 2024 | 5.3% |
| KURA ONCOLOGY INC | 28 | Q2 2024 | 5.1% |
| CORVUS PHARMACEUTICALS INC | 28 | Q1 2024 | 2.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| GLYCOMIMETICS INC | 27 | Q2 2024 | 5.7% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 4 | 2024-08-22 |
| 13F-HR | 2024-08-14 |
| 3 | 2024-08-01 |
| 4 | 2024-06-28 |
| 4 | 2024-06-18 |
| 4 | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.